Stock Analysis·← Pickers

LFCR

Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. (LFCR) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 44.8, with 0/3 trend checks passing.

Price
$4.86
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
44.8
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

LFCR with MA50 and MA200

8.827.536.244.953.6607/3110/2401/2204/1707/15
LFCR2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$5.08-4.28% vs price
MA200
$6.38-23.88% vs price
RSI (14)
44.8Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for LFCR

Lifecore Biomedical, Inc. (LFCR) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $4.86, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 4.3% and below the 200-day moving average by 23.9%.

Momentum and stretch context

LFCR currently has an RSI reading of 44.8, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing LFCR next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Paul Josephs
Employees
382
Market cap
$182.3M
Beta
1.06
52-week range
$3.63 – $8.98
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
15 Feb 1996
ISIN
US5147661046
CUSIP
514766104
Company profile data from Financial Modeling Prep. LFCR listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about LFCR

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.